Medium‐term follow up of active surveillance for early prostate cancer at a non‐academic institution
BJU International · 2024
DOI: 10.1111/bju.16259 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2024. Verfasst von Riccardo Leni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Oncology, Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
To report oncological outcomes of active surveillance (AS) at a single non‐academic institution adopting the standardised Prostate Cancer Research International Active Surveillance (PRIAS) protocol. Patients and Methods Competing risk analyses estimated the incidence of overall mortality, metastases, conversion to treatment, and grade reclassification. The incidence of reclassification and adverse pathological findings at radical prostatectomy were compared between patients fulfilling all PRIAS inclusion criteria vs those not fulfilling at least one.
Results
We analysed 341 men with Grade Group 1 prostate cancer (PCa) followed on AS between 2010 and 2022. There were no PCa deaths, two patients developed distant metastases and were alive at the end of the study period. The 10‐year cumulative incidence of metastases was 1.9% (95% confidence interval [CI] 0.33–6.4%). A total of 111 men were reclassified, and 127 underwent definitive treatment. Men not fulfilling at least one PRIAS inclusion criteria ( n = 43) had a higher incidence of reclassification (subdistribution hazards ratio 1.73, 95% CI 1.07–2.81; P = 0.03), but similar rates of adverse pathological findings at radical prostatectomy.
Conclusion
Metastases in men on AS at a non‐academic institution are as rare as those reported in established international cohorts. Men followed without stringent inclusion criteria should be counselled about the higher incidence of reclassification and reassured they can expect rates of adverse pathological findings comparable to those fulfilling all criteria. Therefore, AS should be proposed to all men with low‐grade PCa regardless of whether they are followed at academic institutions or smaller community hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Experimental Oncology, Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- University of Milano-Bicocca, Milan, Italy.
- Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy.
ORCID-Profile: Marco Roscigno, Francesco Montorsi
Zitieren
APA
Leni, R., Roscigno, M., Barzaghi, P., La Croce, G., Catellani, M., Saccà, A., de Angelis, M., Montorsi, F., Briganti, A., & Da Pozzo, L. F. (2024). Medium‐term follow up of active surveillance for early prostate cancer at a non‐academic institution. BJU International. https://doi.org/10.1111/bju.16259
Vancouver
Leni R, Roscigno M, Barzaghi P, La Croce G, Catellani M, Saccà A, et al. Medium‐term follow up of active surveillance for early prostate cancer at a non‐academic institution. BJU International. 2024. doi:10.1111/bju.16259
BibTeX
@article{Leni2024,
author = {Leni, Riccardo and Roscigno, Marco and Barzaghi, Paolo and La Croce, Giovanni and Catellani, Michele and Saccà, Antonino and de Angelis, Mario and Montorsi, Francesco and Briganti, Alberto and Da Pozzo, Luigi Filippo},
title = {Medium‐term follow up of active surveillance for early prostate cancer at a non‐academic institution},
journal = {BJU International},
year = {2024},
doi = {10.1111/bju.16259}
}
EUVIMED